Michael Okunewitch

Swayampakula Ramakanth

Chase Knickerbocker

Joshua Jennings

Chase Nicheboker

François Brisebois

Josh Jennings

Maya Eskandarani

Michael Okudovich

- MediWound Ltd. entered into a securities purchase agreement on **September 29, 2025**, and closed an offering on **September 30, 2025**, for **1,734,105 ordinary shares** at a purchase price of **$17.30 per share**.  **[1593984_0001178913-25-003451_zk2533825.htm:1]** 
- The offering generated approximately **$30.0 million in gross proceeds**.  **[1593984_0001178913-25-003451_zk2533825.htm:1]** 
- The company intends to use the net proceeds primarily to support **EscharEx®'s pre-commercial activities**, enhance its **large-scale manufacturing capabilities**, and for **general corporate purposes**.  **[1593984_0001178913-25-003451_zk2533825.htm:1]** 
- H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a cash transaction fee equal to **7.0% of the aggregate gross proceeds** (with variations for certain designated investors), a non-accountable expense allowance of **$85,000.00**, and clearing fees of **$15,950.00**.  **[1593984_0001178913-25-003451_zk2533825.htm:1]**

MediWound Ltd. Completes $30 Million Ordinary Share Offering

- **MediWound Ltd.** announced a **$30 million registered direct offering** of **1,734,105 ordinary shares** at a purchase price of **$17.30 per share**.  **[1593984_0001178913-25-003411_zk2533816.htm:0]** **[1593984_0001178913-25-003411_exhibit_99-1.htm:0]** 
- The offering, led by a U.S.-based prominent mutual fund and other healthcare-focused investors, is expected to close on or about **September 30, 2025**.  **[1593984_0001178913-25-003411_exhibit_99-1.htm:0]** 
- The net proceeds from the offering will primarily be used to support **EscharEx's pre-commercial activities**, enhance **large-scale manufacturing capabilities**, and for general corporate purposes.  **[1593984_0001178913-25-003411_exhibit_99-1.htm:0]**

MediWound Announces $30 Million Registered Direct Offering

- MediWound Ltd. (MDWD) announced a registered direct offering of **1,734,105 ordinary shares** at a purchase price of **$17.30 per share**.  **[1593984_899a55d659044d618de9ee1cb409f19f_0]** 
- The offering is expected to generate approximately **$30 million in gross proceeds** for the company.  **[1593984_899a55d659044d618de9ee1cb409f19f_0]** 
- The net proceeds are intended to primarily support **EscharEx’s pre-commercial activities**, enhance **large-scale manufacturing capabilities**, and for general corporate purposes.  **[1593984_899a55d659044d618de9ee1cb409f19f_0]** 
- The offering is expected to close on or about **September 30, 2025**.  **[1593984_899a55d659044d618de9ee1cb409f19f_0]**

MediWound Announces Registered Direct Offering

MediWound (MDWD)